This phase II trial identifies the side effects and the activity of combination chemotherapy and gemtuzumab ozogamicin for the treatment of acute myeloid leukemia that has come back (relapsed) or that does not respond to treatment (refractory). Chemotherapy drugs, such as cladribine and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Granulocyte colony stimulating factor may improve white blood cells after chemotherapy for many cancers including acute myeloid leukemia. Gemtuzumab ozogamicin is a monoclonal antibody, called gemtuzumab, linked to a toxic agent called ozogamicin. Gemtuzumab attaches to CD33 positive cancer cells in a targeted way and delivers ozogamicin to kill them. Other objectives of this trial are to assess how strong the responses are, look at the average length of time patients stay in remission and how long they live, and to see what proportion of patients move onto a stem-cell/bone marrow transplant safely. Also, this trial will look to see whether certain characteristics of leukemia cells are linked to response and survival. Giving combination chemotherapy and gemtuzumab ozogamicin may work better in treating patients with acute myeloid leukemia compared to chemotherapy alone.
Additional locations may be listed on ClinicalTrials.gov for NCT04050280.
Locations matching your search criteria
United States
Maryland
Baltimore
University of Maryland/Greenebaum Cancer CenterStatus: Enrolling By Invitation
Contact: Vu Hong Duong
Phone: 410-328-2567
PRIMARY OBJECTIVES:
I. To assess the efficacy of cladribine, cytarabine, and granulocyte-colony stimulating factor with fractionated gemtuzumab ozogamicin (CLAG-GO) as a salvage regimen for patients with relapsed/refractory acute myeloid leukemia (AML).
II. To evaluate the safety and tolerability of CLAG-GO.
SECONDARY OBJECTIVES:
I. To measure minimal residual disease (MRD) at the end of induction, consolidation and maintenance therapy.
II. To estimate time to relapse or death.
EXPLORATORY OBJECTIVES:
I. To evaluate rate of allogeneic hematopoietic stem cell transplantation (alloHSCT) and safety of alloHSCT after CLAG-GO.
II. To correlate clinical response with karyotype, baseline CD33 expression, CD33 single nucleotide polymorphisms (SNPs).
III. To investigate the changes in sialidase activity, and sialidase and protective protein/cathepsin A (PPCA) expression at both the mRNA and protein levels in leukemia cells before and after administration of gemtuzumab ozogamicin (GO).
IV. To assess the changes in CD33 sialylation in response to GO and correlate them with clinical responses to CLAG-GO.
OUTLINE:
INDUCTION: Patients receive filgrastim or Tbo-filgrastim subcutaneously (SC) daily on days 0-5, gemtuzumab ozogamicin intravenously (IV) over 2 hours on days 1 and 4, cladribine IV over 2 hours daily on days 1-5, and cytarabine IV over 4 hours daily on days 1-5 in the absence of disease progression or unacceptable toxicity . Patients achieving partial remission (PR) may receive a second cycle of induction.
CONSOLIDATION: Patients achieving complete remission (CR), CR without minimal residual disease (CRMRD-), or CR with incomplete blood count recovery (CRi) may receive one cycle of consolidation chemotherapy with CLAG-GO as in Induction phase.
MAINTENANCE: Patients who remain CRMRD-, CR, or CRi may receive gemtuzumab ozogamicin IV over 2 hours on day 1. Treatment repeats every 28 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up for at least 30 days and then every 3 months thereafter.
Lead OrganizationUniversity of Maryland/Greenebaum Cancer Center
Principal InvestigatorVu Hong Duong